About Anuh Pharma Limited
Data last updated:
Anuh Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 19 February 1960 and has been in existence for over 66 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH1960PLC011586. Its GSTIN is 27AAACA4478P1Z5 (Maharashtra). The company holds 2 GST registrations, of which 1 is active. Its shares are listed on BSE: 506260 and NSE: ANUHPHR.
The company has an authorised share capital of ₹51 Cr and a paid-up capital of ₹50.11 Cr. It is led by directors including Ritesh Bipin Shah (Managing Director) and Vivek Bipin Shah (Managing Director).
Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A 3 Shiv Sagar Estatedr Annie Besant Road, Mumbai, Maharashtra, India – 400018.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹771.66 Cr, a growth of 16.7% compared to the previous year. For the same year it recorded a net profit of ₹36.33 Cr (net margin 4.7%) and EBITDA of ₹62.21 Cr (EBITDA margin 8.1%). The net worth stands at ₹352.22 Cr (up 8% YoY). Total assets are valued at ₹354.42 Cr (up 4.6% YoY).
The company has about 212 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Anuh Pharma and SK Age Exports. As per MCA filings, the company has open charges of ₹95 Cr and satisfied charges of ₹112.11 Cr on record. Court records list 17 cases involving the company, including 14 filed by the company and 3 filed against it; 7 cases are pending. The company has 11 deals on record (11 market trades); the latest was in September 2020. Its 10 peer companies in the Pharma industry (API Manufacturers) are compared by revenue, 5 larger and 5 smaller; the largest is Tagoor Laboratories Private Limited with revenue of ₹719.28 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anuhpharma.com.
CIN History of Anuh Pharma Limited
Anuh Pharma has one previous CIN (Corporate Identification Number): U24230MH1960PLC011586. The current CIN is L24230MH1960PLC011586, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230MH1960PLC011586 | Current |
| U24230MH1960PLC011586 | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressA 3 Shiv Sagar Estatedr Annie Besant Road, Mumbai, Maharashtra, India – 400018
- IndustryPharma, API Manufacturers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands with Anuh Pharma Limited
Anuh Pharma operates two associated brands: Anuh Pharma and SK Age Exports. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs, bulk drugs, and formulations are manufactured and traded. | anuhpharma.com | |
| International goods exports are managed from Mumbai, India. | skageexports.com |
Business Activity of Anuh Pharma Limited
The main business activity of Anuh Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Anuh Pharma Limited FY 2025-26 filings available
Anuh Pharma Limited reported revenue of ₹771.66 Cr (up 16.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 772 | 662 | 647 | 527 | 487 | 432 | 307 |
| Revenue growth | +16.7% | +2.2% | +22.7% | +8.4% | +12.7% | +40.7% | - |
| EBITDA | 62.21 | 61.52 | 75.75 | 51.81 | 47.47 | 45.12 | 23.24 |
| EBITDA margin | +8.1% | +9.3% | +11.7% | +9.8% | +9.8% | +10.5% | +7.6% |
| Profit before tax | 54.23 | 61.00 | 78.31 | 47.47 | 39.13 | 38.55 | 19.16 |
| Net profit | 36.33 | 37.62 | 51.89 | 32.94 | 28.60 | 22.49 | 13.25 |
| Net profit margin | +4.7% | +5.7% | +8.0% | +6.2% | +5.9% | +5.2% | +4.3% |
| EPS (₹) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| Balance sheet | |||||||
| Total assets | 354 | 339 | 295 | 244 | 220 | 206 | 209 |
| Net worth | 352 | 326 | 291 | 241 | 214 | 191 | 162 |
| Total debt | 0.06 | 10.89 | 2.69 | 0.91 | 4.22 | 13.68 | 45.15 |
| Cash & bank | 8.30 | 19.74 | 8.37 | 6.65 | 15.95 | 20.09 | 2.52 |
| Net working capital | 204 | 155 | 133 | 95.19 | 110 | 101 | 39.47 |
| Cash flow | |||||||
| Cash from operations | (3.01) | 37.12 | 12.93 | 53.90 | 28.86 | (18.73) | 48.93 |
| Cash from investing | 17.84 | (19.91) | 0.92 | (43.48) | (7.82) | 52.20 | (76.53) |
| Cash from financing | (26.33) | (4.86) | (8.57) | (12.29) | (19.45) | (33.12) | 22.17 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 194 | 202 | 197 | 186 | 186 | 198 | 160 | 166 |
| Revenue growth (YoY) | +3.9% | +2.0% | +23.6% | +12.0% | +35.2% | - | - | - |
| Other income | 3.08 | (1.25) | 1.79 | 0.98 | 3.39 | 1.40 | 0.94 | 3.40 |
| Total expenses | 178 | 182 | 178 | 174 | 176 | 179 | 145 | 149 |
| EBITDA | 16.29 | 19.89 | 19.12 | 11.88 | 10.29 | 18.67 | 14.79 | 16.88 |
| EBITDA margin | +8.4% | +9.8% | +9.7% | +6.4% | +5.5% | +9.4% | +9.3% | +10.2% |
| Depreciation | 2.43 | 3.00 | 3.00 | 2.86 | 2.52 | 2.76 | 2.18 | 1.92 |
| Interest | 0.00 | 0.11 | 0.08 | 0.08 | 0.21 | 0.03 | 0.28 | 0.16 |
| Profit before tax | 16.94 | 15.53 | 17.83 | 9.92 | 10.95 | 17.28 | 13.27 | 18.20 |
| Tax | 5.50 | 3.84 | 4.37 | 2.31 | 2.65 | 4.83 | 2.92 | 3.15 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 194 | 202 | 197 | 186 | 186 | 198 | 160 | 166 |
| Revenue growth (YoY) | +3.9% | +2.0% | +23.6% | +12.0% | +35.2% | - | - | - |
| Other income | 3.08 | (1.25) | 1.79 | 0.98 | 3.39 | 1.40 | 0.94 | 3.40 |
| Total expenses | 178 | 182 | 178 | 174 | 176 | 179 | 145 | 149 |
| EBITDA | 16.29 | 19.89 | 19.12 | 11.88 | 10.29 | 18.67 | 14.79 | 16.88 |
| EBITDA margin | +8.4% | +9.8% | +9.7% | +6.4% | +5.5% | +9.4% | +9.3% | +10.2% |
| Depreciation | 2.43 | 3.00 | 3.00 | 2.86 | 2.52 | 2.76 | 2.18 | 1.92 |
| Interest | 0.00 | 0.11 | 0.08 | 0.08 | 0.21 | 0.03 | 0.28 | 0.16 |
| Profit before tax | 16.94 | 15.53 | 17.83 | 9.92 | 10.95 | 17.28 | 13.27 | 18.20 |
| Tax | 5.50 | 3.84 | 4.37 | 2.31 | 2.65 | 4.83 | 2.92 | 3.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 772 | 662 | 647 | 527 | 487 | 432 | 307 |
| Revenue growth | +16.7% | +2.2% | +22.7% | +8.4% | +12.7% | +40.7% | - |
| Other income | 4.36 | 9.46 | 12.10 | 6.11 | 5.20 | 10.54 | 4.21 |
| Total expenses | 709 | 600 | 571 | 476 | 439 | 387 | 284 |
| Employee cost | 26.30 | 23.04 | 19.39 | 17.15 | 15.10 | 14.29 | 13.36 |
| EBITDA | 62.21 | 61.52 | 75.75 | 51.81 | 47.47 | 45.12 | 23.24 |
| EBITDA margin | +8.1% | +9.3% | +11.7% | +9.8% | +9.8% | +10.5% | +7.6% |
| Depreciation | 11.38 | 8.74 | 8.58 | 9.70 | 11.96 | 15.08 | 7.03 |
| Interest | 0.96 | 1.24 | 0.96 | 0.75 | 1.58 | 2.03 | 1.26 |
| Profit before tax | 54.23 | 61.00 | 78.31 | 47.47 | 39.13 | 38.55 | 19.16 |
| Tax | 13.17 | 13.65 | 18.25 | 11.29 | 8.56 | 10.12 | 4.85 |
| Net profit | 36.33 | 37.62 | 51.89 | 32.94 | 28.60 | 22.49 | 13.25 |
| Net profit margin | +4.7% | +5.7% | +8.0% | +6.2% | +5.9% | +5.2% | +4.3% |
| EPS (₹) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 50.11 | 25.06 | 25.06 | 25.06 | 25.06 | 25.06 | 12.53 |
| Reserves & surplus | 302 | 301 | 266 | 216 | 189 | 166 | 150 |
| Shareholders' funds (net worth) | 352 | 326 | 291 | 241 | 214 | 191 | 162 |
| Secured loans | 0.00 | 10.50 | 2.01 | 0.00 | 3.11 | 13.60 | 44.56 |
| Unsecured loans | 0.06 | 0.39 | 0.68 | 0.91 | 1.11 | 0.08 | 0.59 |
| Total debt | 0.06 | 10.89 | 2.69 | 0.91 | 4.22 | 13.68 | 45.15 |
| Total liabilities | 354 | 339 | 295 | 244 | 220 | 206 | 209 |
| Assets | |||||||
| Gross block | 129 | 120 | 103 | 99.91 | 99.18 | 97.93 | 96.38 |
| Net block | 56.62 | 58.21 | 48.94 | 52.81 | 61.43 | 71.42 | 84.04 |
| Capital work in progress | 0.00 | 0.27 | 0.45 | 0.00 | 0.10 | 0.00 | 0.00 |
| Investments | 84.44 | 106 | 96.77 | 90.83 | 42.68 | 31.39 | 79.56 |
| Inventories | 148 | 74.48 | 75.40 | 72.64 | 79.92 | 81.43 | 61.49 |
| Sundry debtors | 239 | 216 | 190 | 171 | 136 | 107 | 81.03 |
| Cash & bank balances | 8.30 | 19.74 | 8.37 | 6.65 | 15.95 | 20.09 | 2.52 |
| Loans & advances | 11.77 | 12.23 | 9.76 | 5.94 | 5.64 | 18.34 | 12.06 |
| Total current assets | 406 | 322 | 283 | 256 | 237 | 227 | 157 |
| Total current liabilities | 203 | 168 | 150 | 161 | 128 | 126 | 118 |
| Net working capital | 204 | 155 | 133 | 95.19 | 110 | 101 | 39.47 |
| Total assets | 354 | 339 | 295 | 244 | 220 | 206 | 209 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.56 | 7.20 | 1.93 | 3.80 | 2.20 | 1.85 | 7.27 |
| Net cash from operating activities | (3.01) | 37.12 | 12.93 | 53.90 | 28.86 | (18.73) | 48.93 |
| Net cash from investing activities | 17.84 | (19.91) | 0.92 | (43.48) | (7.82) | 52.20 | (76.53) |
| Net cash from financing activities | (26.33) | (4.86) | (8.57) | (12.29) | (19.45) | (33.12) | 22.17 |
| Net change in cash | (11.50) | 12.36 | 5.27 | (1.87) | 1.60 | 0.35 | (5.43) |
| Closing cash | 8.30 | 19.74 | 8.37 | 6.65 | 15.95 | 20.09 | 2.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +16.7% | +2.2% | +22.7% | +8.4% | +12.7% | +40.7% | - |
| EBITDA growth | +1.1% | -18.8% | +46.2% | +9.1% | +5.2% | +94.2% | - |
| PBT growth | -11.1% | -22.1% | +65.0% | +21.3% | +1.5% | +101.2% | -40.9% |
| Net income growth | -3.4% | -27.5% | +57.5% | +15.2% | +27.2% | +69.7% | - |
| Revenue CAGR (3Y) | +13.5% | +10.8% | +14.4% | +19.8% | +14.9% | +22.0% | +14.2% |
| EBITDA CAGR (3Y) | +6.3% | +9.0% | +18.9% | +30.6% | +16.6% | +35.0% | +0.9% |
| Profitability & leverage | |||||||
| Net income margin | +5.3% | +7.2% | +9.3% | +6.9% | +6.3% | +6.6% | +4.7% |
| Return on capital employed | +15.9% | +17.2% | +25.4% | +20.8% | +19.1% | +15.7% | +10.8% |
| Return on net worth | +12.1% | +12.2% | +19.5% | +15.9% | +15.1% | +12.8% | +8.8% |
| Debt / equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.04 | 0.17 | 0.15 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.89 | 2.35 | 1.43 | 1.78 | 4.45 | 6.76 | 7.77 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.19 | 5.93 | 6.38 | 5.30 | 4.94 | 4.45 | 5.00 |
| Inventory turnover | 6.94 | 8.83 | 8.74 | 6.92 | 6.03 | 6.04 | 5.88 |
| Debtors turnover | 3.40 | 3.26 | 3.58 | 3.44 | 4.01 | 4.60 | 3.95 |
| EPS (₹) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| Dividend per share (₹) | 1.50 | 1.50 | 2.50 | 2.00 | 1.75 | 1.50 | 2.75 |
| Book value per share (₹) | 35.14 | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 | 64.74 |
Board of Directors of Anuh Pharma Limited
Anuh Pharma has 12 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arun Lalchand Todarwal Also directs: Arun Todarwal & Associates LLP, Arun Todarwal & Co LLP, Laxmi Organic Industries Limited and 5 more | Director | 24 Oct 2008 | 17 Years 11 Months | Current |
| Bharat Nemchand Shah | Director | 29 Oct 1980 | 45 Years 11 Months | Current |
| Ritesh Bipin Shah Also directs: S Kant Healthcare Limited | Managing Director | 09 Aug 2016 | 10 Years 2 Months | Current |
| Samir Jayantilal Shah Also directs: Eskay Iodine Private Limited, Chaitanya Life Science Private Limited, Skites India LLP and 5 more | Director | 09 Aug 2016 | 10 Years 2 Months | Current |
| Ketan Lalit Shah Also directs: Eskay Iodine Private Limited, Chaitanya Life Science Private Limited, L P Shah Holdings and Trades LLP and 2 more | Director | 09 Aug 2016 | 10 Years 2 Months | Current |
| Bipin Nemchand Shah | Director | 01 Apr 2009 | 17 Years 6 Months | Current |
Peer Comparison of Anuh Pharma Limited
Anuh Pharma Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Anuh Pharma Limited this company | ₹771.66 Cr (FY 2026) | •••• | •••• | 16.7% | •••• | Mumbai, Maharashtra, India |
| Tagoor Laboratories Private Limited | ₹719.28 Cr (FY 2022) | •••• | •••• | 55.0% | •••• | Andhra Pradesh, India |
| Optimus Drugs Private Limited | ₹713.55 Cr (FY 2024) | •••• | •••• | -41.0% | •••• | Hyderabad, Telangana, India |
| Supriya Lifescience Limited Listed | ₹706.3 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Mumbai, Maharashtra, India |
| Dasami Lab Private Limited | ₹694.39 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Chityal, Telangana, India |
| Aaquaries Global Industries Limited | ₹671.02 Cr (FY 2022) | •••• | •••• | 101.0% | •••• | Mumbai, Maharashtra, India |
| RPG Life Sciences Limited Listed | ₹666.11 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Mumbai, Maharashtra, India |
| Ami Lifesciences Pvt Ltd | ₹659.86 Cr (FY 2025) | •••• | •••• | 20.0% | •••• | Vadodara, Gujarat, India |
| Nosch Labs Private Limited | ₹643.87 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Hyderabad, Telangana, India |
| Ind Swift Laboratories Limited Listed | ₹643.09 Cr (FY 2025) | •••• | •••• | -64.0% | •••• | Chandigarh, India |
| Amoli Organics Private Limited | ₹641.59 Cr (FY 2022) | •••• | •••• | 7.0% | •••• | Valsad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Anuh Pharma by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Anuh Pharma Limited
Anuh Pharma Limited is audited by JAYANTILAL THAKKAR & CO. for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| JAYANTILAL THAKKAR & CO. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Shareholding Pattern of Anuh Pharma Limited
Shareholding for the quarter ended Sep 2026: promoters hold 71.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 28.20%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 71.80% | 71.80% | 71.80% | 71.80% |
| Public | 28.20% | 28.20% | 28.20% | 28.20% |
Charges & Borrowings of Anuh Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Feb 2017 | Hdfc Bank Limited | ₹95 Cr | Open |
| 06 Jan 2007 | Bank of India | ₹65 Cr | Satisfied |
| 20 Mar 1999 | Bank of India | ₹25 Lakh | Satisfied |
| 23 Apr 1997 | Bank of India | ₹20 Lakh | Satisfied |
| 19 Jul 1995 | Bank of India | ₹45 Cr | Satisfied |
Total charge records: 11 View all charges
Deals & Funding of Anuh Pharma Limited
Anuh Pharma Limited has 11 deals on record (11 market trades); the latest was in September 2020.
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2020 | Market trade | ₹2.87 Cr | Seller: an individual |
| May 2015 | Market trade | ₹19.77 Cr | Buyer: 2 individuals Seller: L P Shah Holdings and Trades LLP |
| Aug 2010 | Market trade | ₹1.79 Cr | Buyer: an individual Seller: an individual |
| Nov 2009 | Market trade | ₹1.02 Cr | Buyer: an individual |
| Sep 2008 | Market trade | ₹1.26 Cr | Buyer: L P Shah Holding Trades Pvt Ltd Seller: an individual |
Full deal history
All 11 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Anuh Pharma Limited
Anuh Pharma Limited has 17 court cases on record: 14 filed by Anuh Pharma, 3 filed against it. 7 cases are pending and 10 are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 13 | 3 | 5 |
| High courts | 4 | 0 | 2 |
Cases on record (5 of 17)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed by the company against Cian Healthcare Limited | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Cases) | Filed by the company against an individual | Pending |
| Bombay High Court | Writ petition | Filed by the company against Union of India | Pending |
| District court, Thane, Maharashtra | Court case (M.A.C.P.) | Filed against the company by an individual | Pending |
| District court, Thane, Maharashtra | Court case (M.A.C.P.) | Filed against the company by an individual | Pending |
Full case history
All 17 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Anuh Pharma Limited
Anuh Pharma Limited has a workforce of 212 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Anuh Pharma Limited
Anuh Pharma Limited has 32 board changes on record since 1980: 22 appointments and 10 cessations. The latest: Sandeep Madhusudan Joshi ceased to be Director on 21 Aug 2024.
52 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Anuh Pharma Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Anuh Pharma Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Anuh Pharma Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Anuh Pharma Limited
Anuh Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACA4478P1Z5 | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Anuh Pharma Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Anuh Pharma Limited
Frequently Asked Questions about Anuh Pharma Limited
Anuh Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 19 February 1960 (66+ years old) and is registered under CIN L24230MH1960PLC011586. Listed on BSE: 506260 and NSE: ANUHPHR.
Anuh Pharma reported revenue of ₹771.66 Cr for FY 2025-26 (up 16.7% YoY) based on standalone financials.
Anuh Pharma has 12 current directors:
- Ritesh Bipin Shah - Managing Director
- Vivek Bipin Shah - Managing Director
- Arun Lalchand Todarwal - Director
- Bharat Nemchand Shah - Director
- Samir Jayantilal Shah - Director
- Ketan Lalit Shah - Director
- Bipin Nemchand Shah - Director
- Mita Dixit - Director
- Harmanbhai Tulshibhai Patel - Director
- Pradeep Hari Thakur - Director
- Siddharth Shah Jasvantlal - Director
- Gaurav Satish Shah - Director
The GSTIN of Anuh Pharma is 27AAACA4478P1Z5, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Anuh Pharma is L24230MH1960PLC011586. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Anuh Pharma is listed on both BSE (code: 506260) and NSE (symbol: ANUHPHR).
Anuh Pharma has 17 court cases on record: 14 filed by the company and 3 filed against it. 7 are pending. Most are in the district courts.
Anuh Pharma was incorporated on 19 February 1960, making it 66+ years old. It is registered with the Registrar of Companies, Mumbai.
Anuh Pharma has 11 deals on record (11 market trades); the latest was in September 2020.
The peers of Anuh Pharma by revenue are Tagoor Laboratories Private Limited, Optimus Drugs Private Limited, Supriya Lifescience Limited, Dasami Lab Private Limited, Aaquaries Global Industries Limited and 5 more, all in the Pharma industry (API Manufacturers).
Sandeep Madhusudan Joshi ceased to be Director on 21 Aug 2024. Pradeep Hari Thakur was appointed as Director on 01 Apr 2024. Siddharth Shah Jasvantlal was appointed as Director on 01 Apr 2024. Anuh Pharma has 32 board changes on record in total.